Correlation analysis between basal metabolic indexes and the degree of intravesical prostatic protrusion in patients undergoing benign prostatic hyperplasia surgery

doi:10.3877/cma.j.issn.1674-3253.2026.05.009

Abstract

Abstract:

Objective

To investigate the relationship between basal metabolic indexes and the degree of intravesical prostatic protrusion (IPP) in patients undergoing benign prostatic hyperplasia (BPH) surgery.

Methods

Clinical data of 649 BPH patients who underwent surgical treatment at the Department of Urology, the Seventh Affiliated Hospital of Sun Yat-sen University between May 2018 and December 2024 were retrospectively collected. IPP was measured via transabdominal ultrasound. Correlation analysis and generalized linear modeling were employed to examine the associations between IPP and various metabolic indicators, including body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). An age-stratified analysis was also performed.

Results

In the overall population, BMI (r=-0.182, P<0.001), fasting blood glucose (r=-0.118, P<0.01), and TG (r=-0.128, P=0.012) were negatively correlated with IPP, while HDL-C was positively correlated (r=0.118, P= 0.021). Age-stratified analysis revealed a significant negative correlation between BMI and IPP in the groups of 61-70 (r=-0.209) and 71-80 (r=-0.226) years (both P<0.05). A significant negative correlation between TG and IPP was observed in patients over 80 years (r=-0.399, P=0.012). Fasting blood glucose in the group of 61-70 years was significantly negatively correlated with IPP (r=-0.143, P=0.032). Generalized linear modeling confirmed that BMI (β=-0.040, P=0.001) was an independent predictor of IPP, whereas no other metabolic indicators showed independent association.

Conclusion

In BPH patients undergoing surgery, BMI, fasting blood glucose, and TG were negatively correlated with IPP, whereas HDL-C was positively correlated. BMI was an independent predictor of IPP, with age-specific negative associations. Enhanced monitoring of IPP may be warranted in patients aged 61-80 years with low BMI and those over 80 years with decreased TG levels.

Key words: Benign prostatic hyperplasia, Intravesical prostatic protrusion, Body mass index, Blood glucose, Blood lipids

Xinliang Dai, Wei Li, Ziyu Liu, Yuhao Yang, Can Fang, Jun Pang, Donggen Jiang. Correlation analysis between basal metabolic indexes and the degree of intravesical prostatic protrusion in patients undergoing benign prostatic hyperplasia surgery[J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(05): 549-555.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2026.05.009

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2026/V20/I05/549

Figures/Tables 5

References 24

[1]	Awedew AF, Han H, Abbasi B, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Heal Longev, 2022, 3(11): e754-e776. DOI: 10.1016/S2666-7568(22)00213-6.
[2]	Launer BM, McVary KT, Ricke WA, et al. The rising worldwide impact of benign prostatic hyperplasia[J]. BJU Int, 2021, 127(6): 722-728. DOI: 10.1111/bju.15286.
[3]	Song Z, Cheng ZJ, Yuan H, et al. Correlation between benign prostatic hyperplasia and comorbidities: a systematic analysis integrating global burden of disease and Mendelian randomization study[J]. J Transl Med, 2024, 22(1): 1035. DOI: 10.1186/s12967-024-05604-x.
[4]	Wei H, Zhu C, Huang Q, et al. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035[J]. BMC Urol, 2025, 25(1): 34. DOI: 10.1186/s12894-025-01715-9.
[5]	Wang YB, Yang L, Deng YQ, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study[J]. J Transl Med, 2022, 20(1): 495. DOI: 10.1186/s12967-022-03722-y.
[6]	Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia[J]. Mediators Inflamm, 2020, 2020: 7958316. DOI: 10.1155/2020/7958316.
[7]	Fu X, Wang Y, Lu Y, et al. Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection[J]. Life Sci, 2024, 358: 123192. DOI: 10.1016/j.lfs.2024.123192.
[8]	Eze BU, Ani CO, Mbaeri TU. Is intravesical prostatic protrusion associated with more complications in benign prostatic hyperplasia patients?[J]. Low Urin Tract Symptoms, 2021, 13(4): 468-474. DOI: 10.1111/luts.12394.
[9]	Lu CH, Wu HHH, Lin TP, et al. Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients?[J]. J Chin Med Assoc, 2019, 82(5): 381-384. DOI: 10.1097/JCMA.0000000000000088.
[10]	黄健, 张旭. 中国泌尿外科和男科疾病诊断治疗指南:2022版[M]. 北京: 科学出版社, 2022: 475-522.
[11]	Cannarella R, Condorelli RA, Barbagallo F, et al. Endocrinology of the aging prostate: current concepts[J]. Front Endocrinol, 2021, 12: 554078. DOI: 10.3389/fendo.2021.554078.
[12]	Huang J, Chan CK, Yee S, et al. Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis[J]. Prostate Cancer Prostatic Dis, 2023, 26(2): 421-428. DOI: 10.1038/s41391-022-00610-w.
[13]	Hennenberg M, Hu S, Tamalunas A, et al. Genetic predisposition to benign prostatic hyperplasia: where do we stand?[J]. Eur Urol Open Sci, 2024, 70: 154-157. DOI: 10.1016/j.euros.2024.10.012.
[14]	王姊娟, 杜依青, 张建, 等. 代谢综合征及其诊断指标与重度良性前列腺增生症的相关性研究[J]. 协和医学杂志, 2020, 11(6): 703-709. DOI: 10.3969/j.issn.1674-9081.2020.06.012.
[15]	Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023[J]. J Urol, 2024, 211(1): 11-19. DOI: 10.1097/ju.0000000000003698.
[16]	Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial[J]. J Urol, 2007, 177(4): 1395-1400. DOI: 10.1016/j.juro.2006.11.065.
[17]	吴玥, 朱文, 王庆伟, 等. 基于盆底MRI评估年龄与前列腺癌根治术对男性盆底解剖结构及尿控的影响[J]. 临床泌尿外科杂志, 2021, 36(10): 769-775. DOI: 10.13201/j.issn.1001-1420.2021.10.003.
[18]	相晓波, 周童, 李世亮, 等. 良性前列腺增生患者糖脂等指标与前列腺体积的相关性研究[J]. 中华预防医学杂志, 2024, 58(9): 1384-1387. DOI: 10.3760/cma.j.cn112150-20240521-00411.
[19]	桑培培, 程昱璇, 彭薇, 等. 良性前列腺增生患者血清激素水平与前列腺体积的关系[J]. 标记免疫分析与临床, 2022, 29(10): 1638-1642. DOI: 10.11748/bjmy.issn.1006-1703.2022.10.004.
[20]	Kim JH, Han IH, Shin SJ, et al. Signaling role of adipocyte leptin in prostate cell proliferation induced by Trichomonas vaginalis[J]. Korean J Parasitol, 2021, 59(3): 235-249. DOI: 10.3347/kjp.2021.59.3.235.
[21]	Kosmacek EA, Oberley-Deegan RE. Adipocytes protect fibroblasts from radiation-induced damage by adiponectin secretion[J]. Sci Rep, 2020, 10(1): 12616. DOI: 10.1038/s41598-020-69352-w.
[22]	Gharbieh S, Reeves F, Challacombe B. The prostatic middle lobe: clinical significance, presentation and management[J]. Nat Rev Urol, 2023, 20(11): 645-653. DOI: 10.1038/s41585-023-00774-7.
[23]	Zorn KC, Bidair M, Trainer A, et al. Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results[J]. BJUI Compass, 2022, 3(2): 130-138. DOI: 10.1002/bco2.121.
[24]	Eure G, Rukstalis D, Roehrborn C. Prostatic urethral lift for obstructive Median lobes: consistent results across controlled trial and real-world settings[J]. J Endourol, 2023, 37(1): 50-59. DOI: 10.1089/end.2022.0324.

变量	数值	Kolmogorov-Smirnov检验
年龄[岁，M(Q)]	68 (62，75)	D=0.057，P<0.001
BMI [kg/m²，(±s)]	24.06±3.09	D=0.025，P=0.200
SBP [mmHg，M(Q)]	132 (121，144)	D=0.036，P=0.045
DBP [mmHg，M(Q)]	80 (73，87）	D=0.036，P=0.041
TC [mmol/L，(±s)]	4.65±1.08	D=0.041，P=0.064
TG [mmol/L，M(Q)]	1.22 (0.88，1.74)	D=0.220，P<0.001
LDL-C [mmol/L，M(Q)]	2.73 (2.12，3.25)	D=0.059，P=0.001
HDL-C [mmol/L，M(Q)]	1.10 (0.94，1.32)	D=0.079，P<0.001
空腹血糖[mmol/L，M(Q)]	5.54 (5.03，6.65)	D=0.154，P<0.001
IPP [mm，M(Q)]	8.75 (4.70，14.00)	D=0.099，P<0.001

变量	数值	Kolmogorov-Smirnov检验
年龄[岁，M(Q)]	68 (62，75)	D=0.057，P<0.001
BMI [kg/m²，(±s)]	24.06±3.09	D=0.025，P=0.200
SBP [mmHg，M(Q)]	132 (121，144)	D=0.036，P=0.045
DBP [mmHg，M(Q)]	80 (73，87）	D=0.036，P=0.041
TC [mmol/L，(±s)]	4.65±1.08	D=0.041，P=0.064
TG [mmol/L，M(Q)]	1.22 (0.88，1.74)	D=0.220，P<0.001
LDL-C [mmol/L，M(Q)]	2.73 (2.12，3.25)	D=0.059，P=0.001
HDL-C [mmol/L，M(Q)]	1.10 (0.94，1.32)	D=0.079，P<0.001
空腹血糖[mmol/L，M(Q)]	5.54 (5.03，6.65)	D=0.154，P<0.001
IPP [mm，M(Q)]	8.75 (4.70，14.00)	D=0.099，P<0.001

	≤60岁			61～70岁			71～80岁			>80岁
	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值
BMI (kg/m²)	107	-0.099	0.311	236	-0.209	0.001	131	-0.226	0.010	51	-0.108	0.449
空腹血糖(mmol/L)	97	-0.134	0.192	227	-0.143	0.032	124	-0.104	0.250	51	0.039	0.784
TG (mmol/L)	70	0.075	0.539	169	-0.143	0.064	105	-0.179	0.068	39	-0.399	0.012
HDL-C(mmol/L)	70	0.081	0.504	169	0.097	0.211	105	0.189	0.053	39	0.186	0.258

	≤60岁			61～70岁			71～80岁			>80岁
	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值	例数(n)	相关系数(r)	P值
BMI (kg/m²)	107	-0.099	0.311	236	-0.209	0.001	131	-0.226	0.010	51	-0.108	0.449
空腹血糖(mmol/L)	97	-0.134	0.192	227	-0.143	0.032	124	-0.104	0.250	51	0.039	0.784
TG (mmol/L)	70	0.075	0.539	169	-0.143	0.064	105	-0.179	0.068	39	-0.399	0.012
HDL-C(mmol/L)	70	0.081	0.504	169	0.097	0.211	105	0.189	0.053	39	0.186	0.258

变量	系数(β)	标准误(Sx)	95%CI	Exp (β)	P值
截距	3.207	0.494	(2.238，4.175)	24.693	<0.001
年龄（岁）	-0.000	0.004	(-0.008，0.008)	1.000	0.996
BMI(kg/m²)	-0.040	0.012	(-0.063，-0.016)	0.961	0.001
空腹血糖(mmol/L)	-0.034	0.023	(-0.080，0.012)	0.967	0.145
TG(mmol/L)	0.038	0.022	(-0.005，0.081)	1.039	0.086
HDL-C(mmol/L)	0.198	0.120	(-0.037，0.433)	1.219	0.098

Please choose a citation manager

Content to export